* NRX Pharmaceuticals Inc reported a quarterly adjusted loss of 13 cents​​ per share for the quarter , higher than the same quarter last year, when the company reported EPS of -70 cents. The mean expectation of three analysts for the quarter was for a loss of 64 cents per share. Wall Street expected results to range from -81 cents to -45 cents per share.

* Reported revenue was zero​; analysts expected zero.

* NRX Pharmaceuticals Inc's reported EPS for the quarter was a loss of 15 cents​.

* The company reported a quarterly loss of $1.62 million.

* NRX Pharmaceuticals Inc shares had fallen by 31.4% this quarter and lost 74.8% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 7.2% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for NRX Pharmaceuticals Inc is $31.00 This summary was machine generated from LSEG data November 15 at 02:09 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.64 -0.13 Beat

Jun. 30 2024 -0.69 -0.67 Beat

Mar. 31 2024 -0.55 -0.74 Missed

Dec. 31 2023 -0.70 -0.50 Beat